Details der Publikation - ILd therapy for RRMM patients

Medienart:	Klinische Studie

Erscheinungsjahr:	2021
Erschienen:	2021

Enthalten in:	WHO International Clinical Trials Registry Platform - (2021) vom: 27. Dez. Zur Gesamtaufnahme - year:2021

Sprache:	Englisch

Links:	Volltext [kostenfrei]

Themen:	610 Medical Condition: Multiple myeloma Recruitment Status: Recruiting Study Type: Interventional

Anmerkungen:	WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 09-08-2019, Last updated: 2022-11-24

ICTRP ID:	JPRN-jRCTs071190019

Förderinstitution / Projekttitel:

PPN (Katalog-ID):	CTG006622658


LEADER	01000caa a22002652 4500
001	CTG006622658
003	DE-627
005	20230425165725.0
007	cr uuu---uuuuu
008	210507s2021 xx \|\|\|\|\|o 00\| \|\|eng c
035			\|a (DE-627)CTG006622658
035			\|a (UBBS_Klinische_Studien_WHO)JPRN-jRCTs071190019
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
245	1	0	\|a ILd therapy for RRMM patients \|b Efficacy and safety of ixazomib, lenalidomide and dexamethasone (ILd) combination therapy for the relapsed and refractory multiple myeloma patients undergoing lenalidomide maintenance - W-JHS MM02
264		1	\|c 2021
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 09-08-2019, Last updated: 2022-11-24
650		4	\|a Medical Condition: Multiple myeloma
650		4	\|a Study Type: Interventional
650		4	\|a Recruitment Status: Recruiting
650		4	\|a 610
773	0	8	\|i Enthalten in \|t WHO International Clinical Trials Registry Platform \|g (2021) vom: 27. Dez.
773	1	8	\|g year:2021 \|g day:27 \|g month:12
856	4	0	\|u https://jrct.niph.go.jp/latest-detail/jRCTs071190019 \|z kostenfrei \|3 Volltext
912			\|a GBV_CTG
912			\|a SSG-OLC-PHA
951			\|a AR
952			\|j 2021 \|b 27 \|c 12